Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Colchicine today.

Elisabeth Niel1, Jean-Michel Scherrmann

  • 1Inserm U705, UMR CNRS 7157, Neuropsychopharmacologie des Addictions, Hôpital Fernand-Widal, Universités Paris-V et -VII, 200, rue du Faubourg-Saint-Denis, 75475 Paris cedex 10, France.

Joint Bone Spine
|October 28, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Functional and targeted proteomics characterization of a human primary endothelial cell model of the blood-brain barrier (BBB) for drug permeability studies.

Toxicology and applied pharmacology·2023
Same author

Epidemiokinetic Tools to Monitor Lockdown Efficacy and Estimate the Duration Adequate to Control SARS-CoV-2 Spread.

Journal of epidemiology and global health·2021
Same author

Is Curfew Effective in Limiting SARS-CoV-2 Progression? An Evaluation in France Based on Epidemiokinetic Analyses.

Journal of general internal medicine·2021
Same author

Brain Distribution of Drugs: Brain Morphology, Delivery Routes, and Species Differences.

Handbook of experimental pharmacology·2021
Same author

Is Lockdown Effective in Limiting SARS-CoV-2 Epidemic Progression?-a Cross-Country Comparative Evaluation Using Epidemiokinetic Tools.

Journal of general internal medicine·2021
Same author

Possible Role of ABCB1 in Lysosomal Accumulation of Azithromycin in COVID-19 Therapy.

Clinical pharmacology and therapeutics·2020

Colchicine, used for gout and inflammatory diseases, has complex pharmacokinetics influenced by tubulin, CYP3A4, and P-glycoprotein. Therapeutic effects correlate with leukocyte levels, not plasma concentrations, necessitating careful monitoring.

Area of Science:

  • Pharmacology
  • Drug Metabolism
  • Inflammatory Diseases

Background:

  • Colchicine is a key treatment for gout and familial Mediterranean fever (FMF).
  • Its pharmacokinetics are complex, involving multiple proteins.
  • Understanding these processes is crucial for effective and safe use.

Purpose of the Study:

  • To elucidate the pharmacokinetic profile of colchicine.
  • To identify key proteins involved in colchicine's absorption, distribution, metabolism, and excretion.
  • To correlate pharmacokinetic parameters with pharmacodynamic effects and adverse events.

Main Methods:

  • Pharmacokinetic studies utilizing radioimmunoassay to measure blood colchicine levels.
  • Analysis of absorption, volume of distribution, protein binding, and elimination half-life.

Related Experiment Videos

  • Investigation of drug interactions involving CYP3A4 and P-glycoprotein.

    • Main Results:

    • Variable oral absorption (24-88%) and a large volume of distribution (7 L/kg).
    • Chiefly hepatic excretion with an elimination half-life of 20-40 hours.
    • Therapeutic effects correlate with leukocyte levels, not plasma concentrations.

    Conclusions:

    • Colchicine's pharmacokinetics are significantly influenced by tubulin, CYP3A4, and P-glycoprotein.
    • Monitoring leukocyte levels is more indicative of therapeutic effect than plasma levels.
    • Drug interactions with CYP3A4/P-glycoprotein inhibitors increase toxicity risk, requiring vigilant patient monitoring.